Navigation Links
Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
Date:11/28/2007

CHICAGO, Nov. 28 /PRNewswire/ -- Radiologists are using a new minimally invasive procedure to treat tendonitis in the shoulder. Ultrasound-guided non-surgical therapy significantly reduces pain from calcific tendonitis of the rotator cuff and restores mobility, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

"This is a quick, successful and inexpensive therapy for tendon calcifications," said Luca M. Sconfienza, M.D., from the Department of Radiology at A.O. Ospedale Santa Corona in Pietra Ligure and the Department of Experimental Medicine at the University of Genova in Italy. "It provides significant and long-lasting reduction of symptoms."

Calcific tendonitis is a condition that causes the formation of small calcium deposits within the tendons of the rotator cuff in the shoulder. It is most common in adults 30 to 40 years old. In most cases, the deposits become painful and can restrict mobility of the shoulder. In minor cases, physical therapy or anti-inflammatory medications may be sufficient to address the problem until the calcifications break apart spontaneously. In severe cases, patients may require shockwave treatment or open surgery to remove the calcium.

Ultrasound-guided percutaneous (through the skin) therapy represents an effective and inexpensive alternative to surgery that is less stressful for the patient. For the 10-minute procedure, the shoulder is anesthetized and, with ultrasound guidance, a radiologist injects a saline solution into the rotator cuff to wash the area and break up the calcium. A second needle is used to aspirate, or withdraw, the calcium residue. Recovery time is about an hour. Calcifications that are completely treated do not ever return.

"Calcifications can break up on their own. Unfortunately, this can take from a few months to several years," Dr. Sconfienza said. "This means the pain could persist for years before its spontaneous resolution."

In addition, when untreated calcifications break up, the calcium is not extracted but spreads along the tendon and lodges in the subacromial bursa, a fluid sac that helps lubricate the tendon. Calcium buildup in the tendon and bursa can cause bursitis, a painful condition with a long recovery time and a high grade of disability.

For the study, Dr. Sconfienza and colleagues used ultrasound-guided percutaneous therapy to treat 2,543 shoulders in 1,607 women and 938 men (mean age 42) with calcific tendonitis. All of the patients had shoulder pain that was unresponsive to previous medical treatment. One-year follow-up was reported for 2,018 of the patients in the study.

The results showed that in 71.7 percent of the patients, the calcification was fully aspirated in one treatment with a considerable reduction in pain and significant improvement to mobility of the affected limb. In 23.6 percent of patients, a second procedure was performed because of the presence of more than one calcification. In 3.8 percent of patients, the calcification had dissolved or moved before treatment could take place. In 0.9 percent of patients, no resolution of symptoms occurred because of the presence of a tendon tear.

While Ospedale Santa Corona and the University of Genova are among few institutions currently offering this new therapy, Dr. Sconfienza says that theoretically, the procedure could be performed in any hospital or clinic that has ultrasound equipment with a superficial probe.

"As people age, many complain of pain in the shoulders. This pain is commonly caused by calcium build-up," Dr. Sconfienza said. "This procedure can allow them to feel better immediately with little cost."

Co-authors are F. Lacelli, M.D., M. Gravano, M.D., G. Serafini, M.D., G. Garlaschi, M.D., and E. Silvestri, M.D.

AT A GLANCE

-- A large-scale study found that minimally invasive, ultrasound-guided

percutaneous therapy effectively treats tendonitis caused by calcium

deposits in the shoulder.

-- The therapy takes about 10 minutes, is inexpensive and resulted in a

considerable reduction in symptoms in a majority of patients in the

study.

-- Calcific tendonitis typically affects 30- to 40-year-olds and can cause

pain and a reduction in shoulder mobility.

Note: Copies of RSNA 2007 news releases and electronic images will be available online at RSNA.org/press07 beginning Monday, Nov. 26.

RSNA is an association of more than 41,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The Society is based in Oak Brook, Ill. (RSNA.org)

Editor's note: The data in these releases may differ from those in the printed abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312-949-3233.


'/>"/>
SOURCE Radiological Society of North America
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):